ptd : great buy, page-4

looks like this "cancer" scare has spooked a lot of small investors. the risk of lymphomas were already known when the anti-tnf drugs were seeking fda approval. that's why you need to be monitored closely when you are pescribed with this medication. furthermore, this class of drug is given when all other treatment modalities fail. so to me most people will rather want to improve their quality of life by taking this medication than to be frightened by the risk of cancer. there are no other options available at the moment and it is highly unlikely that fda will suspend the drug, so this bad publicity represents yet another good opportunity to collect the share imo..